Suicidality and Antidepressant Drugs
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies with Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of Marplan or any other antidepressant in a child, adolescent or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Marplan is not approved for use in pediatric patients. (See Warnings: Clinical Worsening and Suicide Risk, Precautions: Information for Patients, and Precautions: Pediatric Use)
Pooled analyses of short-term (4 to 16 weeks) placebo-controlled trials of 9 antidepressant drugs (SSRIs and others) in children and adolescents with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders (a total of 24 trials involving over 4400 patients) have revealed a greater risk of adverse events representing suicidal thinking or behavior (suicidality) during the first few months of treatment in those receiving antidepressants. The average risk of such events in patients receiving antidepressants was 4%, twice the placebo risk of 2%. No suicides occurred in these trials.
brand of isocarboxazid
Marplan (isocarboxazid), a monoamine oxidase inhibitor, is available for oral administration in 10-mg tablets.
Marplan is indicated for the treatment of depression. Because of its potentially serious side effects, Marplan is not an antidepressant of first choice in the treatment of newly diagnosed depressed patients.
The efficacy of Marplan in the treatment of depression was established in 6-week controlled trials of depressed outpatients. These patients had symptoms that corresponded to the DSM-IV category of major depressive disorder; however, they often also had signs and symptoms of anxiety (anxious mood, panic, and/or phobic symptoms) (See CLINICAL PHARMACOLOGY).
A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation.
The antidepressant effectiveness of Marplan in hospitalized depressed patients, or in endogenomorphically retarded and delusionally depressed patients, has not been adequately studied.
The effectiveness of Marplan in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use Marplan for extended periods should periodically evaluate the long-term usefulness of the drug for the individual patient.
Media Articles Related to Marplan (Isocarboxazid)
Metabolic Disorders Linked to Severe, Refractory Depression
Source: Medscape Psychiatry & Mental Health Headlines [2017.01.12]
A large proportion of patients with severe, refractory depression have neurometabolic disorders that, once treated, appear to cause depressive symptoms to remit over the long term.
Medscape Medical News
OncoBreak: Cancer and Depression; Diagno$tic Te$t$; New Watson Study
Source: MedPage Today Gastroenterology [2017.01.12]
(MedPage Today) -- News, features, and commentary about cancer-related issues
New apps designed to reduce depression and anxiety as easily as checking your phone
Source: Anxiety / Stress News From Medical News Today [2017.01.09]
Soon you can seek mental health advice on your smartphone as quickly as finding a good restaurant.
ADHD and Depression: What's the Connection?
Source: ADHD / ADD News From Medical News Today [2016.12.29]
ADHD conjures up thoughts of hyperactivity and energy, but depression can also be a symptom. Find out how depression and ADHD are linked.
How to avoid Facebook-induced depression
Source: Depression News From Medical News Today [2016.12.29]
A review has been conducted to analyze the link between Facebook use and depression. The research has highlighted some ways to avoid 'Facebook depression.'
Published Studies Related to Marplan (Isocarboxazid)
Moclobemide in depression: a randomized, multicentre trial against isocarboxazide and clomipramine emphasizing atypical depression. [1991.12]
Moclobemide was compared with isocarboxazide and clomipramine in patients with depression. A total of 167 outpatients were allocated to daily treatment with 300 mg moclobemide, 30 mg isocarboxazide or 150 mg clomipramine for 6 weeks... Anticholinergic symptoms and orthostatic hypotension were most pronounced in the clomipramine group.
A trial of isocarboxazid in the treatment of bulimia nervosa. [1988.12]
Eighteen women completed a double-blind, placebo-controlled crossover study designed to investigate the effects of isocarboxazid in the treatment of bulimia nervosa. There was a significant reduction in binge eating and vomiting during isocarboxazid treatment... There were no serious adverse effects from this monoamine oxidase inhibitor therapy, although over 50% of patients elected to discontinue isocarboxazid 1 year after the study.
An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology. [1988.02]
Isocarboxazid and placebo were evaluated in 130 anxious depressives. Drug was superior to placebo on depression, anxiety, interpersonal sensitivity, and global measures, and on symptoms of hostility, anxiety, obsessiveness, and psychological-cognitive components of depression...
[Prolonged hyperthermia after isocarboxazid poisoning] [2003.04.28]
A 44-year-old unconscious man was admitted 24 hours after intake of approximately one gram of isocarboxazid. He was subsequently intubated for seven days... Massive rhabdomyolysis was treated with forced diuresis.
Disruption of FR-40 by 5-HT agonists. II. Effects of chronic phenelzine or isocarboxazid. [1989.10]
Effects of chronic treatment with the monoamine oxidase inhibitors phenelzine and isocarboxazid on disruption of FR-40 operant responses by 5-HT agonists have been studied. Three groups of rats that were trained in the FR-40 operant schedule showed marked disruption by 0.1 mg/kg IP lysergic acid diethylamide (LSD), 2 mg/kg IP quipazine (Q), 0.05 mg/kg SC 8-hydroxy-2-(di-n-propylamino)tetralin (8-OHDPAT), and 1 mg/kg SC (m-trifluoromethyl-phenyl)piperazine (TFMPP), administered twice weekly in random order...
Clinical Trials Related to Marplan (Isocarboxazid)
I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers [Recruiting]
The imdazoline2 binding site (I2BS) is known to reside inside astrocytes. Changes in the
numbers of I2BS in post mortem tissue has implicated them in a range of psychiatric
conditions such as depression and addiction, along with neurodegenerative disorders such as
Alzheimer's disease and Huntington's chorea. Preclinical studies have also demonstrated
functional interactions with the opioid system, where I2BS ligands have been shown to affect
tolerance to morphine and alleviate some of the morphine withdrawal syndrome in rats.
Recently the I2BS and I2BS ligands have been shown to have some interesting analgesic
effects in different models of pain and a novel I2BS ligand, CR4056, is currently undergoing
Phase II clinical trials as a novel treatment for neuropathic pain and acute non- specific
The location of I2BS on astrocytic glial cells and the possibility that they may in some way
regulate glial fibrillary acidic protein have led to increased interest into the role of
I2BS and I2BS ligands in conditions characterised by marked gliosis. The number of I2BS has
been shown to increase in Alzheimer's disease post mortem, and it has also been suggested
that I2BS may be a marker for the severity and malignancy of human glioblastomas.
The lack of suitable imaging tools for the I2BS has meant that information regarding the
number and distribution of I2BS in the brain has come from preclinical species and in vitro
post-mortem studies. The recent development of [11C]BU99008 as a suitable PET ligand to
quantify I2BS in vivo, enables the direct quantification of I2BS availability and regional
distribution in the living human brain. In this study the investigators plan to utilise
[11C]BU99008 to quantify the regional brain availability of I2BS in the human brain in vivo
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism [Completed]
Reduction of volume of the hippocampus has been associated with major depression in many
studies. It has been suggested that antidepressants may protect against hippocampus volume
loss in humans associated with multiple episodes of depression and may also reverse the
reduction of volume caused by the depression. In addition, genetic markers for serotonin are
implicated with depression, and may be an indication of reduced response to antidepressant
This study aims to enroll patients who are defined as having treatment resistant depression
(no remission after at least 2 treatments trials with an antidepressant). They will receive
an MRI scan at the initial visit and either 6 months after sustained remission or 12 months
after they enter the study for non-remitters. They will also be asked to give a blood sample
for genotyping. They will be matched by age and handedness to healthy volunteers with no
personal history of depression who will also receive an MRI scan and genotyping.
The first aim is to compare hippocampal volume of depressed subjects to healthy controls. It
is anticipated that subjects will initially have smaller hippocampal volume but of those who
sustain remission, there will be a small increase in hippocampal volume. It is also
anticipated that specific genetic markers will be related to individuals response to
Page last updated: 2017-01-12